{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:42:06Z","timestamp":1792676526140,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neurol.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:54:34Z","timestamp":1776383674000},"page":"389-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cell therapy in multiple sclerosis: An overview"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-7794","authenticated-orcid":false,"given":"L.","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neurol.2026.03.012_bib0140","first-page":"275","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: results of the ASTIMS randomized trial","volume":"14","author":"Mancardi","year":"2015","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.03.012_bib0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: the MIST randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.neurol.2026.03.012_bib0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder\u00a0\u2013\u00a0recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"21","key":"10.1016\/j.neurol.2026.03.012_bib0155","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.03.012_bib0160","first-page":"103821","article-title":"Autologous hematopoietic stem cell transplantation outcomes in multiple sclerosis: a systematic review and meta-analysis of 50 studies","volume":"62","author":"Nabizadeh","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.neurol.2026.03.012_bib0165","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.neurol.2026.03.012_bib0170","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1177\/1352458514564484","article-title":"Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study","volume":"21","author":"Curr\u00f2","year":"2015","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.neurol.2026.03.012_bib0175","first-page":"1914","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.neurol.2026.03.012_bib0180","first-page":"206","article-title":"Rituximab improves peripheral B-cell abnormalities in human systemic lupus erythematosus","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.neurol.2026.03.012_bib0185","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"23","key":"10.1016\/j.neurol.2026.03.012_bib0190","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis: results from a phase I clinical trial","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2026.03.012_bib0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.neurol.2026.03.012_bib0200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/stem.3077","article-title":"Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells","volume":"38","author":"M\u00e9nard","year":"2020","journal-title":"Stem Cells"},{"key":"10.1016\/j.neurol.2026.03.012_bib0205","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.mayocp.2019.01.001","article-title":"Mesenchymal stromal cell therapies for neurodegenerative diseases","volume":"94","author":"Staff","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.neurol.2026.03.012_bib0210","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/stem.194","article-title":"Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis","volume":"27","author":"Constantin","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.neurol.2026.03.012_bib0215","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.exphem.2009.09.004","article-title":"Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages","volume":"37","author":"Kim","year":"2009","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.neurol.2026.03.012_bib0220","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","article-title":"Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue","volume":"24","author":"Kern","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.neurol.2026.03.012_bib0225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1423-0127-18-49","article-title":"Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells","volume":"18","author":"Chen","year":"2011","journal-title":"J Biomed Sci"},{"issue":"12","key":"10.1016\/j.neurol.2026.03.012_bib0230","first-page":"2249","article-title":"Distinct immunomodulatory and angiogenic properties of mesenchymal stromal cells from different human tissues","volume":"22","author":"Payne","year":"2013","journal-title":"Cell Transplant"},{"issue":"9","key":"10.1016\/j.neurol.2026.03.012_bib0235","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/00207454.2022.2042690","article-title":"Opportunities and challenges: mesenchymal stem cells in the treatment of multiple sclerosis","volume":"133","author":"Zhang","year":"2023","journal-title":"Int J Neurosci"},{"issue":"6","key":"10.1016\/j.neurol.2026.03.012_bib0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"Suppl. 1","key":"10.1016\/j.neurol.2026.03.012_bib0245","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3727\/096368914X685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis","volume":"23","author":"Li","year":"2014","journal-title":"Cell Transplant"},{"key":"10.1016\/j.neurol.2026.03.012_bib0250","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.012_bib0255","doi-asserted-by":"crossref","first-page":"e0195891","DOI":"10.1371\/journal.pone.0195891","article-title":"Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study","volume":"13","author":"Fern\u00e1ndez","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2026.03.012_bib0260","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.03.012_bib0265","doi-asserted-by":"crossref","first-page":"639315","DOI":"10.3389\/fneur.2021.639315","article-title":"Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis","volume":"12","author":"Petrou","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2026.03.012_bib0270","doi-asserted-by":"crossref","first-page":"105681","DOI":"10.1016\/j.msard.2024.105681","article-title":"Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): an updated systematic review and meta-analysis","volume":"87","author":"Vaheb","year":"2024","journal-title":"Mult Scler Relat Disord"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:15:20Z","timestamp":1792674920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0035378726005060"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.03.012","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell therapy in multiple sclerosis: An overview","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}